A multicentre, prospective observational cohort study to assess the effects of vildagliptin relative to sulphonylurea as dual therapy with metformin (or as monotherapy) in Muslim patients with type 2 diabetes fasting during Ramadan

drug protocol number
CLAF237A-MAX-AE-02
drug sponsor
Novartis
drug study
Vildagliptin / Sulphonylurea / Metformin
drug trial site
Soliman Fakeeh Hospital (Jeddah)
drug status
Completed
drug phase